Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy-Reference-Cited by-同舟云学术

Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy

Published:2011-09-02 Issue:3 Volume:26 Page:368-373
ISSN:0269-8811
Container-title:Journal of Psychopharmacology
language:en
Short-container-title:J Psychopharmacol

Author:

Rybakowski Janusz K¹,Czerski Piotr²,Dmitrzak-Weglarz Monika²,Kliwicki Sebastian¹,Leszczynska-Rodziewicz Anna¹,Permoda-Osip Agnieszka¹,Skibinska Maria²,Suwalska Aleksandra¹,Szczepankiewicz Aleksandra³,Hauser Joanna²

Affiliation:

1. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

2. Psychiatric Genetics Unit, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

3. Laboratory of Cellular and Molecular Analysis, Department of Pediatric Pulmonology, Allergy and Clinical Immunology, IIIrd Department of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland

Abstract

A number of candidate genes for lithium prophylactic efficacy have been proposed, some of them being also associated with a predisposition to bipolar illness. The aim of the present study was to investigate a possible association between polymorphisms of 14 common genes with the quality of prophylactic lithium response in patients with bipolar mood disorder, in relation to the putative role of these genes in the pathogenesis of this disorder. Some association with lithium prophylactic efficacy was found for the polymorphisms of 5HTT, DRD1, COMT, BDNF and FYN genes, but not for 5HT2A, 5HT2C, DRD2, DRD3, DRD4, GSK-3, NTRK2, GRIN2B and MMP-9. Possible aspects of these genes with regard to the mechanism of lithium activity and pathogenesis of bipolar mood disorder are discussed.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/0269881111415736

Reference41 articles.

1. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

2. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial

3. Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1)

4. Dopamine Receptor D₁ Gene –48A/G Polymorphism Is Associated with Bipolar Illness but Not with Schizophrenia in a Polish Population

5. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder;Neuroscience & Biobehavioral Reviews;2022-11

2. Studies on candidate genes for lithium prophylaxis performed at the Poznan University of Medical Sciences;Psychiatria Polska;2022-10-31

3. Genetic and Epigenetic Markers of Lithium Response;International Journal of Molecular Sciences;2022-01-29

4. Pharmacogenomics and mood stabilizers: efficacy and adverse drug reactions;Psychiatric Genomics;2022

5. Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder;Neurosciences;2021-10